As­traZeneca CEO Pas­cal So­ri­ot sev­ers an un­usu­al board con­nec­tion, steer­ing clear of con­flicts while re­tain­ing im­por­tant al­liances

Yesterday
Bioregnum

Af­ter 3 deaths rock the field, gene ther­a­py re­searchers con­tem­plate AAV's fu­ture

2 days ago
In Focus

Vivek Ra­maswamy and Matt Gline pen share­hold­er let­ters about the changes now un­der­way at Roivant

3 days ago
People

Scoop: Vivek Ra­maswamy is hand­ing the CEO job to a top lieu­tenant at Roivant — but he’s not ex­act­ly leav­ing the biotech scene

3 days ago
Bioregnum

Al­bireo just ad­vanced down to the 10-yard line at the FDA. And Ron Coop­er’s team is get­ting prepped for the next big play

3 days ago
Regulatory

What does $29B buy you in Big Phar­ma? In Glax­o­SmithK­line’s case, a whole lot of un­com­fort­able ques­tions about the pipeline

6 days ago
R&D

As coro­n­avirus vari­ants trig­ger new alarms, the NIH is putting an un­der-the-radar ‘next-gen’ vac­cine in­to PhI

Last week
Discovery

Pssst: That big Bio­haven Alzheimer's study? It was a bust. Even the sub­group analy­sis ex­ecs tout­ed was a flop

Last week
Bioregnum

Paint­ing by the num­bers, Sana founders carve up a gi­ant uni­corn-sized IPO — for a biotech that has­n't quite made it to the clin­ic

2 weeks ago
Financing

With a tor­rent of ven­ture cash gush­ing from a glob­al pack of uni­corn hunters, this biotech founder vows to stay hun­gry

3 weeks ago
Financing

A vet­er­an on­col­o­gy start­up crew is mak­ing a very se­ri­ous bet that they’ve found the key to un­lock­ing the promise of on­colyt­ic virus­es

4 weeks ago
Financing
Startups

It was the best of all pos­si­ble worlds in the worst of all times for biotech in 2020. What comes now?

4 weeks ago
Financing

John Con­nol­ly has a new mis­sion to tack on to his role at the Park­er In­sti­tute: in­ter­im chief of a buzzy biotech backed by a pair of bil­lion­aires

Last month
Bioregnum

Backed by a $200M in­vest­ment from a Ko­re­an con­glom­er­ate, Vivek Ra­maswamy has qui­et­ly built a ‘moth­er ship’ for vant cre­ation — with a whole new strat­e­gy in mind

Last month
Deals

The FDA spells out 4 rea­sons why it hates Min­er­va’s NDA ideas — but the biotech is go­ing for it any­way

Last month
Regulatory

Cap­ping Pas­cal So­ri­ot’s big turn­around, the an­a­lysts at Cowen say As­traZeneca is poised for a stel­lar year

Last month
Bioregnum
R&D

The ad­u­canum­ab co­nun­drum: The PhI­II failed a clear reg­u­la­to­ry stan­dard, but no one is cer­tain what that means any­more at the FDA

2 months ago
Bioregnum
Regulatory

From a pair of Air Jor­dans to a $200M-plus IPO, Carl Hansen is craft­ing an overnight R&D for­tune fu­eled by Covid-19

2 months ago
Financing

TCR pi­o­neer Im­muno­core scores a first with a land­mark PhI­II snap­shot on over­all sur­vival for a rare melanoma

2 months ago
R&D

Scoop: SR One crew com­pletes a com­pli­cat­ed spin­out from Glax­o­SmithK­line. And now they have a $500M fund to in­vest on their own

2 months ago
Financing

Rene­go­ti­ate the $6B CVR deal Bris­tol My­ers made for the Cel­gene buy­out? Caforio says that’s not hap­pen­ing

2 months ago
Deals

A phar­ma R&D chief jumps to a bud­ding new start­up fac­to­ry — and this time he’s found 'some­thing com­plete­ly dif­fer­ent’

2 months ago
People
Startups

What do the top 10 biotech M&A deals of 2020 tell us? Pre­mi­ums are in, bolt-ons rule and the ADC come­back is on

2 months ago
Startups
Deals

Sean Bo­hen just wrote the hand­book on how to make a quick for­tune in biotech

2 months ago
People
Financing
1234 Next page Last page